AM152 regulatory update

FDA granted Orphan Drug designation for Amira's AM152 to treat idiopathic pulmonary fibrosis (IPF). The oral lysophosphatidic acid receptor 1 ( LPAR1; EDG2; LPA1) antagonist is in Phase I testing t...